[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$anab](/topic/$anab)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$anab/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$anab/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XXX% +50%  
**6 Months**: XXX% +10%  
**1 Year**: XXX% no change  
**1-Year High**: XXX% on 2025-01-26  
**1-Year Low**: XX% on 2025-09-10  

**Most Supportive Themes**
- **Company Split and Buyback:** (40%) Positive sentiment surrounds the announcement of AnaptysBio's split into two companies and a $75M buyback program.
- **Positive RA Trial Data:** (30%) The lead candidate rosnilimab's positive data in rheumatoid arthritis trials is generating excitement.
- **Analyst Upgrades and Price Targets:** (20%) Multiple analysts have raised price targets for $ANAB, indicating confidence in the stock's potential.
  
**Most Critical Themes**
- **Market Competition:** (10%)  Concerns exist regarding the competitive landscape of the RA treatment market.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %   | Negative | %  |
| ------- | -------- | -  | ------- | -   | -------- | -  |
| X       | XX       | X% | XXX     | XX% | XX       | X% |
| YouTube | X        | X% | X       | X%  | X        | X% |
|         |          |    |         |     |          |    |
| Total   | XX       | X% | XXX     | XX% | XX       | X% |